Alnylam Historical Financial Ratios
ALNY Stock | USD 149.13 2.09 1.38% |
Alnylam Pharmaceuticals is presently reporting on over 111 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, Days Sales Outstanding of 60.78 or Free Cash Flow Yield of 0.0018 will help investors to properly organize and evaluate Alnylam Pharmaceuticals financial condition quickly.
Alnylam |
About Alnylam Financial Ratios Analysis
Alnylam PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Alnylam Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Alnylam financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Alnylam Pharmaceuticals history.
Alnylam Pharmaceuticals Financial Ratios Chart
Alnylam Pharmaceuticals financial ratios usually calculated using numerical values taken directly from Alnylam Pharmaceuticals financial statements such as income statements or balance sheets. They help investors to obtain meaningful information about Alnylam Pharmaceuticals. Most financial ratios help to conduct quantitative analysis to assess vital information about the company's valuation as well as profitability and liquidity indicators such as leverage, growth, profit margins, and different types of rates of return.
At this time, Alnylam Pharmaceuticals' Intangibles To Total Assets are fairly stable compared to the past year. Current Ratio is likely to rise to 5.83 in 2024, whereas Price To Sales Ratio is likely to drop 12.42 in 2024. Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Alnylam Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Alnylam Pharmaceuticals sales, a figure that is much harder to manipulate than other Alnylam Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company’s stock price to its revenues, calculated by dividing the company’s market cap by its total sales or revenue over a 12-month period.Inventory Turnover
A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.Most ratios from Alnylam Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Alnylam Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.At this time, Alnylam Pharmaceuticals' Intangibles To Total Assets are fairly stable compared to the past year. Current Ratio is likely to rise to 5.83 in 2024, whereas Price To Sales Ratio is likely to drop 12.42 in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 1.91 | 1.72 | 5.59 | 5.87 | Days Of Inventory On Hand | 319.57 | 278.83 | 104.82 | 99.58 |
Alnylam Pharmaceuticals fundamentals Correlations
Click cells to compare fundamentals
Alnylam Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Alnylam Pharmaceuticals fundamentals Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Price To Sales Ratio | 57.26 | 30.32 | 23.79 | 27.88 | 13.08 | 12.42 | |
Ptb Ratio | 8.75 | 14.71 | 34.15 | (182.78) | (108.36) | (102.94) | |
Days Sales Outstanding | 71.44 | 75.85 | 85.85 | 83.72 | 65.44 | 60.78 | |
Book Value Per Share | 13.17 | 8.84 | 4.97 | (1.3) | (1.77) | (1.68) | |
Free Cash Flow Yield | (0.0333) | (0.0459) | (0.0357) | (0.0212) | 0.001754 | 0.001842 | |
Invested Capital | 0.4 | 0.51 | 1.7 | (8.34) | (11.06) | (10.5) | |
Operating Cash Flow Per Share | (2.55) | (5.35) | (5.42) | (4.45) | 0.83 | 0.88 | |
Capex To Depreciation | (2.58) | (0.95) | (0.85) | (0.84) | (1.15) | (1.21) | |
Pb Ratio | 8.75 | 14.71 | 34.15 | (182.78) | (108.36) | (102.94) | |
Ev To Sales | 56.16 | 30.37 | 24.0 | 28.31 | 14.1 | 13.39 | |
Free Cash Flow Per Share | (3.83) | (5.96) | (6.06) | (5.04) | 0.34 | 0.35 | |
Roic | (0.47) | (0.54) | (0.45) | (0.68) | (0.13) | (0.14) | |
Inventory Turnover | 0.44 | 0.85 | 1.14 | 1.31 | 3.48 | 3.66 | |
Net Income Per Share | (8.11) | (7.46) | (7.2) | (9.3) | (3.52) | (3.7) | |
Days Of Inventory On Hand | 820.65 | 431.64 | 319.57 | 278.83 | 104.82 | 99.58 | |
Payables Turnover | 0.5 | 1.5 | 1.91 | 1.72 | 5.59 | 5.87 | |
Sales General And Administrative To Revenue | 5.1 | 2.18 | 1.19 | 0.74 | 0.44 | 0.41 | |
Research And Ddevelopement To Revenue | 2.98 | 1.33 | 0.94 | 0.85 | 0.55 | 0.52 | |
Capex To Revenue | (0.64) | (0.14) | (0.0905) | (0.0695) | (0.034) | (0.0357) | |
Cash Per Share | 14.06 | 16.3 | 20.56 | 18.02 | 19.53 | 10.34 | |
Pocfratio | (45.2) | (24.3) | (31.3) | (53.43) | 229.54 | 241.02 | |
Capex To Operating Cash Flow | 0.5 | 0.11 | 0.12 | 0.13 | (0.6) | (0.57) | |
Pfcf Ratio | (30.06) | (21.81) | (27.97) | (47.15) | 569.99 | 598.49 | |
Days Payables Outstanding | 726.5 | 243.01 | 191.24 | 212.09 | 65.28 | 62.02 | |
Roe | (0.62) | (0.84) | (1.45) | 7.15 | 2.0 | 2.1 | |
Ev To Operating Cash Flow | (44.32) | (24.34) | (31.58) | (54.27) | 247.5 | 259.87 | |
Pe Ratio | (14.2) | (17.41) | (23.55) | (25.57) | (54.31) | (51.59) | |
Ev To Free Cash Flow | (29.48) | (21.84) | (28.22) | (47.89) | 614.57 | 645.3 | |
Earnings Yield | (0.0704) | (0.0574) | (0.0425) | (0.0391) | (0.0184) | (0.0193) | |
Net Debt To E B I T D A | 0.26 | (0.0319) | (0.25) | (0.51) | (8.2) | (7.79) | |
Current Ratio | 1.81 | 1.91 | 2.41 | 3.51 | 3.08 | 5.83 | |
Tangible Book Value Per Share | 13.17 | 8.84 | 4.97 | (3.47) | (7.35) | (6.99) | |
Receivables Turnover | 5.11 | 4.81 | 4.25 | 4.36 | 5.58 | 5.3 | |
Graham Number | 49.02 | 38.53 | 28.36 | 16.49 | 11.84 | 11.24 | |
Shareholders Equity Per Share | 13.17 | 8.84 | 4.97 | (1.3) | (1.77) | (1.68) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.C | Citigroup | |
CRM | Salesforce | |
MSFT | Microsoft |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Complementary Tools for Alnylam Stock analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
Is Alnylam Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alnylam Pharmaceuticals. If investors know Alnylam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alnylam Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.64) | Revenue Per Share 15.974 | Quarterly Revenue Growth 0.548 | Return On Assets (0.03) | Return On Equity (15.01) |
The market value of Alnylam Pharmaceuticals is measured differently than its book value, which is the value of Alnylam that is recorded on the company's balance sheet. Investors also form their own opinion of Alnylam Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Alnylam Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alnylam Pharmaceuticals' market value can be influenced by many factors that don't directly affect Alnylam Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alnylam Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alnylam Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alnylam Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.